Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CBLB | Q13191 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22220775 | 0.82 | CA2 (0.47) | ADRB3CA2EGFRTNNI3KALOX12 | |
| SCHEMBL10191948 | 0.81 | HPGD (0.46) | ADRB3 | |
| SCHEMBL10100499 | 0.76 | KEAP1 (0.55) | CA2EGFRTNNI3KBRD4 | |
| SCHEMBL6830181 | 0.76 | AR (0.50) | CA2PGR | |
| SCHEMBL10876109 | 0.74 | CDK1 (0.52) | CA2 | |
| SCHEMBL693060 | 0.74 | ADRB3 (0.39) | ADRB3BRD4 | |
| SCHEMBL14508412 | 0.73 | CA2 (0.55) | CA2EGFRTNNI3KALOX12PGR | |
| SCHEMBL13181439 | 0.73 | KDM1A (0.48) | ADRB3CA2EGFRTNNI3KALOX12 | |
| SCHEMBL27182647 | 0.72 | CA2 (0.50) | CA2EGFRTNNI3KALOX12PGR | |
| SCHEMBL10169501 | 0.71 | KDM4E (0.35) | CA2EGFRTNNI3KALOX12PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | ADRB3 2669/4885CA2 2566/4885EGFR 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.